The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 105 results:
Author Title Type [ Year(Asc)]
Filters: Author is Katsiki, Niki  [Clear All Filters]
2022
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
2019
Soulaidopoulos, S., Pagkopoulou E., Katsiki N., Triantafyllidou E., Karagiannis A., Garyfallos A., et al. (2019).  Arterial stiffness correlates with progressive nailfold capillary microscopic changes in systemic sclerosis: results from a cross-sectional study.. Arthritis Res Ther. 21(1), 253.
Reklou, A., Katsiki N., Karagiannis A., & Athyros V. (2019).  Effects of lipid lowering drugs on arterial stiffness. One more way to reduce cardiovascular risk?. Curr Vasc Pharmacol.
Anagnostis, P., Paschou S. A., Katsiki N., Krikidis D., Lambrinoudaki I., & Goulis D. G. (2019).  Menopausal Hormone Therapy and Cardiovascular Risk: Where are we Now?. Curr Vasc Pharmacol. 17(6), 564-572.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Katsiki, N., Anagnostis P., Kotsa K., Goulis D. G., & Mikhailidis D. P. (2019).  Obesity, Metabolic Syndrome and the Risk of Microvascular Complications in Patients with Diabetes mellitus.. Curr Pharm Des. 25(18), 2051-2059.
Antonopoulou, V., Karras S. N., Koufakis T., Yavropoulou M., Katsiki N., Gerou S., et al. (2019).  Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism.. J Surg Res. 245, 22-30.
2018
Rizos, C. V., Elisaf M. S., Skoumas I., Tziomalos K., Kotsis V., Rallidis L., et al. (2018).  Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).. Atherosclerosis. 277, 308-313.
Athyros, V. G., Katsiki N., & Doumas M. (2018).  Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis.. Curr Vasc Pharmacol. 16(2), 104-106.
Katsiki, N., MSc V. Kolovou, PhD A. Tsipis Md, PhD C. Mihas Md, Md V. Vartela, PhD M. Koutelou M., et al. (2018).  Gene Polymorphisms in Cardiovascular Disease and Cancer.. Angiology. 69(8), 738-739.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Doumas, M., Katsiki N., & Papademetriou V. (2018).  Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology. 69(1), 5-9.
Kolovou, V., Tsipis A., Mihas C., Katsiki N., Vartela V., Koutelou M., et al. (2018).  Tumor Protein p53 (TP53) Gene and Left Main Coronary Artery Disease.. Angiology. 69(8), 730-735.
2017
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2017).  Semaglutide, lipid-lowering drugs, and NAFLD.. Lancet Diabetes Endocrinol. 5(5), 329-330.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.. Metabolism. 71, 17-32.
Athyros, V. G., Alexandrides T. K., Bilianou H., Cholongitas E., Doumas M., Ganotakis E. S., et al. (2017).  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 71, 17 - 32.
2016
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?. Curr Vasc Pharmacol. 14(6), 494-497.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Editorial: Cardiovascular Disease Mortality Rates are Plateauing in Certain Age Groups and Regions. Can we Keep them Declining?. Curr Vasc Pharmacol. 14(3), 271-4.
Katsiki, N., Athyros V. G., & Karagiannis A. (2016).  Exploring the Management of Statin Intolerant Patients: 2016 and Beyond.. Curr Vasc Pharmacol. 14(6), 523-533.
Katsiki, N., Doumas M., & Mikhailidis D. P. (2016).  Lipids, Statins and Heart Failure: An Update.. Curr Pharm Des. 22(31), 4796-4806.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and non-alcoholic steatohepatitis.. J Hepatol. 64(1), 241-2.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2016).  Statins and Type 2 Diabetes Mellitus: An Update After 1 Year.. Curr Pharm Des. 22(18), 2723-5.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. Curr Vasc Pharmacol. 14(1), 88-97.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.